+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cancer Immunotherapy Market Size, Share & Trends Analysis Report, Product, Application, Distribution (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End Use, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 110 Pages
  • December 2023
  • Region: Global
  • Grand View Research
  • ID: 4429682
Description Jump to:
The global cancer immunotherapy market size is expected to reach USD 224.30 billion by 2030, registering a CAGR of 8.3% from 2024 to 2030. The rising adoption of the immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth. For instance, in October 2021, the U.S. FDA approved Tecentriq (atezolizumab), of Genentech, Inc for the treatment of NSCLC.

Moreover, the robust product pipeline of the immunotherapy medicines for oncology is one of the major driving factors for strong growth of the market. For instance, (phase-III), developed by AstraZeneca for the treatment of first-line stage small cell lung malignancy. Immuno-oncology agents have shown promising results with improved survival rates and less toxicity. Such clinical trial results are expected to increase the introduction of novel therapeutic options in the coming years.

Increasing adoption of the combination therapies to treat cancer is further expected to increase demand for the immunotherapy. Combination therapies target multiple pathways within the tumor microenvironment that can potentially increase effectiveness of the immunotherapeutic treatment. Companies are mainly emphasizing development of the targeted treatments as novel regimens for the oncology disorder treatment.

The introduction of immunotherapy has aided the treatment options for the malignancies of breast, brain, bladder, lymphomas, and others. Although the usage of this therapy is minimal as compared to chemotherapy, radiotherapy, and surgery. Immunotherapy is anticipated to emerge as the leading treatment strategy for the malignancies during the next few years. The alarming rise in oncology incidence rates has provoked global collaboration on oncology drugs and other therapies. For instance, in March 2020, Astellas Pharma and CytomX collaborated to expand pipeline of the next-generation Immuno-oncology treatments. This collaboration has helped companies to strengthen their immune-oncology portfolio.

Furthermore, development and approval of the novel immunotherapy treatments for relapsed and refractory malignancies are accelerating the cancer immunotherapy market expansion. For instance, in February 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of CARVYKTI from the U.S. FDA for treatment of the refractory multiple myeloma after four or more lines of treatment.

Cancer Immunotherapy Market Report Highlights

  • Monoclonal antibodies segment held the largest market share in 2023 owing to rising investments in the R&D of monoclonal antibodies
  • By product, the oncolytic viral therapies & cancer vaccines sub-segment is anticipated to grow at the fastest rate owing to their greater clinical benefit to patients with advanced-stage malignancies
  • Based on application, lung cancer dominated the market owing to the rise in prevalence of the disease and increasing adoption of immunotherapy for the treatment
  • The prostate cancer sub-segment is likely to register the fastest CAGR due to the increasing awareness about prostate cancer and rising product launch
  • The hospitals & clinics segment led the market in 2023 owing to the increasing demand for immunotherapeutic medicines in hospitals and increasing hospitalization of cancer patients
  • Asia-Pacific is expected to exhibit the fastest growth during the forecast period due to the growing establishment of healthcare, and high unmet medical needs
  • Key market players are continuously involved in the development of novel treatments and geographical expansion, in order to expand their footprint in the global market.


This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Application
1.2.3. Distribution
1.2.4. End Use
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia-Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product
2.2.2. Application
2.2.3. Distribution
2.2.4. End Use
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. Cancer Immunotherapy Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of cancer
3.2.1.2. Growing R&D activities by pharmaceutical companies
3.2.1.3. Technological advancements and introduction of novel drugs
3.2.2. Market restraint analysis
3.2.2.1. Risk of side effects associated with the treatment
3.2.2.2. High cost of therapy and unfavorable reimbursement scenario
3.3. Cancer Immunotherapy Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Cancer Immunotherapy Market: Product Estimates & Trend Analysis
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Cancer Immunotherapy Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Monoclonal Antibodies
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Immunomodulators
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Oncolytic Viral Therapies and Cancer Vaccines
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Cancer Immunotherapy Market: Application Estimates & Trend Analysis
5.1. Application Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Cancer Immunotherapy Market by Application Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Lung Cancer
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Breast Cancer
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Colorectal Cancer
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Melanoma
5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.5. Prostate Cancer
5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.6. Head and Neck Cancer
5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.7. Ovarian Cancer
5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.8. Pancreatic Cancer
5.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.9. Others
5.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Cancer Immunotherapy Market: Distribution Estimates & Trend Analysis
6.1. Distribution Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Cancer Immunotherapy Market by Distribution Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Hospital Pharmacy
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.4.2. Retail Pharmacy
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Online Pharmacy
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Cancer Immunotherapy Market: End Use Estimates & Trend Analysis
7.1. Distribution Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global Cancer Immunotherapy Market by End Use Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Hospitals & Clinics
7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
7.4.2. Cancer Research Centers
7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. Others
7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Cancer Immunotherapy Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2023 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
8.5. North America
8.5.1. U.S.
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
8.5.2. Canada
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Europe
8.6.1. UK
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
8.6.2. Germany
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
8.6.3. France
8.6.3.1. Key country dynamics
8.6.3.2. Regulatory framework/reimbursement structure
8.6.3.3. Competitive scenario
8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
8.6.4. Italy
8.6.4.1. Key country dynamics
8.6.4.2. Regulatory framework/reimbursement structure
8.6.4.3. Competitive scenario
8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
8.6.5. Spain
8.6.5.1. Key country dynamics
8.6.5.2. Regulatory framework/reimbursement structure
8.6.5.3. Competitive scenario
8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
8.6.6. Norway
8.6.6.1. Key country dynamics
8.6.6.2. Regulatory framework/reimbursement structure
8.6.6.3. Competitive scenario
8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
8.6.7. Sweden
8.6.7.1. Key country dynamics
8.6.7.2. Regulatory framework/reimbursement structure
8.6.7.3. Competitive scenario
8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
8.6.8. Denmark
8.6.8.1. Key country dynamics
8.6.8.2. Regulatory framework/reimbursement structure
8.6.8.3. Competitive scenario
8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.7. Asia-Pacific
8.7.1. Japan
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
8.7.2. China
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
8.7.3. India
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
8.7.4. Australia
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
8.7.5. South Korea
8.7.5.1. Key country dynamics
8.7.5.2. Regulatory framework/reimbursement structure
8.7.5.3. Competitive scenario
8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
8.7.6. Thailand
8.7.6.1. Key country dynamics
8.7.6.2. Regulatory framework/reimbursement structure
8.7.6.3. Competitive scenario
8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.8. Latin America
8.8.1. Brazil
8.8.1.1. Key country dynamics
8.8.1.2. Regulatory framework/ reimbursement structure
8.8.1.3. Competitive scenario
8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
8.8.2. Mexico
8.8.2.1. Key country dynamics
8.8.2.2. Regulatory framework/ reimbursement structure
8.8.2.3. Competitive scenario
8.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.8.3. Argentina
8.8.3.1. Key country dynamics
8.8.3.2. Regulatory framework/ reimbursement structure
8.8.3.3. Competitive scenario
8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.9. MEA
8.9.1. South Africa
8.9.1.1. Key country dynamics
8.9.1.2. Regulatory framework/ reimbursement structure
8.9.1.3. Competitive scenario
8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
8.9.2. Saudi Arabia
8.9.2.1. Key country dynamics
8.9.2.2. Regulatory framework/ reimbursement structure
8.9.2.3. Competitive scenario
8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
8.9.3. UAE
8.9.3.1. Key country dynamics
8.9.3.2. Regulatory framework/ reimbursement structure
8.9.3.3. Competitive scenario
8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
8.9.4. Kuwait
8.9.4.1. Key country dynamics
8.9.4.2. Regulatory framework/reimbursement structure
8.9.4.3. Competitive scenario
8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company market share analysis, 2023
9.3.4. Pfizer Inc.
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Product benchmarking
9.3.4.4. Strategic initiatives
9.3.5. AstraZeneca
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Product benchmarking
9.3.5.4. Strategic initiatives
9.3.6. Merck & Co., Inc
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Product benchmarking
9.3.6.4. Strategic initiatives
9.3.7. F. Hoffmann-La Roche Ltd
9.3.7.1. Company overview
9.3.7.2. Financial performance
9.3.7.3. Product benchmarking
9.3.7.4. Strategic initiatives
9.3.8. Bristol-Myers Squibb Company
9.3.8.1. Company overview
9.3.8.2. Financial performance
9.3.8.3. Product benchmarking
9.3.8.4. Strategic initiatives
9.3.9. Novartis AG
9.3.9.1. Company overview
9.3.9.2. Financial performance
9.3.9.3. Product benchmarking
9.3.9.4. Strategic initiatives
9.3.10. Lilly
9.3.10.1. Company overview
9.3.10.2. Financial performance
9.3.10.3. Product benchmarking
9.3.10.4. Strategic initiatives
9.3.11. Johnson & Johnson Services, Inc
9.3.11.1. Company overview
9.3.11.2. Financial performance
9.3.11.3. Product benchmarking
9.3.11.4. Strategic initiatives
9.3.12. Immunocore, Ltd
9.3.12.1. Company overview
9.3.12.2. Financial performance
9.3.12.3. Product benchmarking
9.3.12.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America Cancer Immunotherapy market, by region, 2018-2030 (USD Million)
Table 3 North America Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 4 North America Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 5 North America Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 6 North America Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 7 US Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 8 US Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 9 US Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 10 US Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 11 Canada Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 12 Canada Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 13 Canada Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 14 Canada Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 15 Europe Cancer Immunotherapy market, by region, 2018-2030 (USD Million)
Table 16 Europe Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 17 Europe Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 18 Europe Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 19 Europe Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 20 Germany Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 21 Germany Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 22 Germany Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 23 Germany Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 24 UK Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 25 UK Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 26 UK Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 27 UK Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 28 France Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 29 France Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 30 France Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 31 France Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 32 Italy Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 33 Italy Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 34 Italy Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 35 Italy Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 36 Spain Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 37 Spain Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 38 Spain Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 39 Spain Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 40 Denmark Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 41 Denmark Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 42 Denmark Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 43 Denmark Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 44 Sweden Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 45 Sweden Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 46 Sweden Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 47 Sweden Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 48 Norway Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 49 Norway Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 50 Norway Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 51 Norway Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 52 Asia-Pacific Cancer Immunotherapy market, by region, 2018-2030 (USD Million)
Table 53 Asia-Pacific Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 54 Asia-Pacific Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 55 Asia-Pacific Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 56 Asia-Pacific Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 57 China Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 58 China Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 59 China Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 60 China Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 61 Japan Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 62 Japan Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 63 Japan Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 64 Japan Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 65 India Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 66 India Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 67 India Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 68 India Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 69 South Korea Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 70 South Korea Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 71 South Korea Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 72 South Korea Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 73 Australia Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 74 Australia Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 75 Australia Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 76 Australia Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 77 Thailand Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 78 Thailand Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 79 Thailand Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 80 Thailand Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 81 Latin America Cancer Immunotherapy market, by region, 2018-2030 (USD Million)
Table 82 Latin America Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 83 Latin America Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 84 Latin America Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 85 Latin America Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 86 Brazil Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 87 Brazil Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 88 Brazil Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 89 Brazil Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 90 Mexico Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 91 Mexico Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 92 Mexico Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 93 Mexico Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 94 Argentina Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 95 Argentina Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 96 Argentina Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 97 Argentina Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 98 MEA Cancer Immunotherapy market, by region, 2018-2030 (USD Million)
Table 99 MEA Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 100 MEA Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 101 MEA Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 102 MEA Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 103 South Africa Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 104 South Africa Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 105 South Africa Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 106 South Africa Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 107 Saudi Arabia Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 108 Saudi Arabia Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 109 Saudi Arabia Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 110 Saudi Arabia Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 111 UAE Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 112 UAE Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 113 UAE Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 114 UAE Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
Table 115 Kuwait Cancer Immunotherapy market, by product, 2018-2030 (USD Million)
Table 116 Kuwait Cancer Immunotherapy market, by application, 2018-2030 (USD Million)
Table 117 Kuwait Cancer Immunotherapy market, by distribution, 2018-2030 (USD Million)
Table 118 Kuwait Cancer Immunotherapy market, by end use, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews in North America
Figure 5 Primary interviews in Europe
Figure 6 Primary interviews in APAC
Figure 7 Primary interviews in Latin America
Figure 8 Primary interviews in MEA
Figure 9 Market research approaches
Figure 10 Value-chain-based sizing & forecasting
Figure 11 QFD modeling for market share assessment
Figure 12 Market formulation & validation
Figure 13 Cancer Immunotherapy market: market outlook
Figure 14 Cancer Immunotherapy competitive insights
Figure 15 Parent market outlook
Figure 16 Related/ancillary market outlook
Figure 17 Penetration and growth prospect mapping
Figure 18 Industry value chain analysis
Figure 19 Cancer Immunotherapy market driver impact
Figure 20 Cancer Immunotherapy market restraint impact
Figure 21 Cancer Immunotherapy market strategic initiatives analysis
Figure 22 Cancer Immunotherapy market: Product movement analysis
Figure 23 Cancer Immunotherapy market: Product outlook and key takeaways
Figure 24 Monoclonal Antibodies market estimates and forecast, 2018-2030
Figure 25 Immunomodulators market estimates and forecast, 2018-2030
Figure 26 Oncolytic Viral Therapies and Cancer Vaccines market estimates and forecast, 2018-2030
Figure 27 Cancer Immunotherapy Market: Application movement Analysis
Figure 28 Cancer Immunotherapy market: Application outlook and key takeaways
Figure 29 Lung Cancer market estimates and forecasts, 2018-2030
Figure 30 Breast Cancer market estimates and forecasts, 2018-2030
Figure 31 Colorectal Cancer market estimates and forecasts, 2018-2030
Figure 32 Melanoma market estimates and forecasts, 2018-2030
Figure 33 Prostate Cancer market estimates and forecasts, 2018-2030
Figure 34 Head and Neck Cancer market estimates and forecasts, 2018-2030
Figure 35 Ovarian Cancer market estimates and forecasts, 2018-2030
Figure 36 Pancreatic Cancer market estimates and forecasts, 2018-2030
Figure 37 Others market estimates and forecasts, 2018-2030
Figure 38 Cancer Immunotherapy market: Distribution movement analysis
Figure 39 Cancer Immunotherapy market: Distribution outlook and key takeaways
Figure 40 Hospital Pharmacy market estimates and forecasts, 2018-2030
Figure 41 Retail Pharmacy market estimates and forecasts, 2018-2030
Figure 42 Online Pharmacy market estimates and forecasts, 2018-2030
Figure 43 Cancer Immunotherapy market: End Use movement analysis
Figure 44 Cancer Immunotherapy market: End Use outlook and key takeaways
Figure 45 Hospitals & Clinics market estimates and forecasts, 2018-2030
Figure 46 Cancer Research Centers market estimates and forecasts, 2018-2030
Figure 47 Others market estimates and forecasts, 2018-2030
Figure 48 Global Cancer Immunotherapy market: Regional movement analysis
Figure 49 Global Cancer Immunotherapy market: Regional outlook and key takeaways
Figure 50 Global Cancer Immunotherapy market share and leading players
Figure 51 North America market share and leading players
Figure 52 Europe market share and leading players
Figure 53 Asia-Pacific market share and leading players
Figure 54 Latin America market share and leading players
Figure 55 Middle East & Africa market share and leading players
Figure 56 North America: SWOT
Figure 57 Europe SWOT
Figure 58 Asia-Pacific SWOT
Figure 59 Latin America SWOT
Figure 60 MEA SWOT
Figure 61 North America, by country
Figure 62 North America
Figure 63 North America market estimates and forecasts, 2018-2030
Figure 64 U.S.
Figure 65 U.S. market estimates and forecasts, 2018-2030
Figure 66 Canada
Figure 67 Canada market estimates and forecasts, 2018-2030
Figure 68 Europe
Figure 69 Europe market estimates and forecasts, 2018-2030
Figure 70 UK
Figure 71 UK market estimates and forecasts, 2018-2030
Figure 72 Germany
Figure 73 Germany market estimates and forecasts, 2018-2030
Figure 74 France
Figure 75 France market estimates and forecasts, 2018-2030
Figure 76 Italy
Figure 77 Italy market estimates and forecasts, 2018-2030
Figure 78 Spain
Figure 79 Spain market estimates and forecasts, 2018-2030
Figure 80 Denmark
Figure 81 Denmark market estimates and forecasts, 2018-2030
Figure 82 Sweden
Figure 83 Sweden market estimates and forecasts, 2018-2030
Figure 84 Norway
Figure 85 Norway market estimates and forecasts, 2018-2030
Figure 86 Asia-Pacific
Figure 87 Asia-Pacific market estimates and forecasts, 2018-2030
Figure 88 China
Figure 89 China market estimates and forecasts, 2018-2030
Figure 90 Japan
Figure 91 Japan market estimates and forecasts, 2018-2030
Figure 92 India
Figure 93 India market estimates and forecasts, 2018-2030
Figure 94 Thailand
Figure 95 Thailand market estimates and forecasts, 2018-2030
Figure 96 South Korea
Figure 97 South Korea market estimates and forecasts, 2018-2030
Figure 98 Australia
Figure 99 Australia market estimates and forecasts, 2018-2030
Figure 100 Latin America
Figure 101 Latin America market estimates and forecasts, 2018-2030
Figure 102 Brazil
Figure 103 Brazil market estimates and forecasts, 2018-2030
Figure 104 Mexico
Figure 105 Mexico market estimates and forecasts, 2018-2030
Figure 106 Argentina
Figure 107 Argentina market estimates and forecasts, 2018-2030
Figure 108 Middle East and Africa
Figure 109 Middle East and Africa market estimates and forecasts, 2018-2030
Figure 110 South Africa
Figure 111 South Africa market estimates and forecasts, 2018-2030
Figure 112 Saudi Arabia
Figure 113 Saudi Arabia market estimates and forecasts, 2018-2030
Figure 114 UAE
Figure 115 UAE market estimates and forecasts, 2018-2030
Figure 116 Kuwait
Figure 117 Kuwait market estimates and forecasts, 2018-2030
Figure 118 Market share of key market players- Cancer Immunotherapy market

Companies Mentioned

  • Pfizer Inc.
  • AstraZeneca
  • Merck & Co., Inc
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Lilly
  • Johnson & Johnson Services, Inc
  • Immunocore, Ltd

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages110
PublishedDecember 2023
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 125.69 Billion
Forecasted Market Value ( USD ) by 2030 $ 224.3 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Cancer Immunotherapy Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Drug Type (Monoclonal antibodies, Immunomodulators), By Cancer Type (Lung, Breast), By Service Type, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Cancer Immunotherapy Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Drug Type (Monoclonal antibodies, Immunomodulators), By Cancer Type (Lung, Breast), By Service Type, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 98 Pages
  • Global
From
Global Cancer Immunotherapy Market by Product (Cell Therapies, Checkpoint Inhibitors, Immunomodulators), Function (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-User - Forecast 2024-2030 - Product Image

Global Cancer Immunotherapy Market by Product (Cell Therapies, Checkpoint Inhibitors, Immunomodulators), Function (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-User - Forecast 2024-2030

  • Report
  • 195 Pages
  • Global
From
Global Neoantigen Targeted Therapies Market by Target Disease Indication (Bone Cancer, Colorectal Cancer, Gynecological Cancer), Neoantigens Type (Off-the-Shelf Neoantigens, Personalized Neoantigens), Immunotherapy Type, Route of Administration - Forecast 2024-2030 - Product Image

Global Neoantigen Targeted Therapies Market by Target Disease Indication (Bone Cancer, Colorectal Cancer, Gynecological Cancer), Neoantigens Type (Off-the-Shelf Neoantigens, Personalized Neoantigens), Immunotherapy Type, Route of Administration - Forecast 2024-2030

  • Report
  • 199 Pages
  • Global
From
Liver Cancer Drug Market Size, Share & Trends Analysis Report By Drug Class (Targeted Therapy, Immunotherapy, Chemotherapy), By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Liver Cancer Drug Market Size, Share & Trends Analysis Report By Drug Class (Targeted Therapy, Immunotherapy, Chemotherapy), By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 92 Pages
  • Global
From
Cancer Immunotherapy Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis - Product Image

Cancer Immunotherapy Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis

  • Report
  • 190 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.